UH Rainbow enrolls first patient in rare blood disorder study
University Hospitals Rainbow participates in landmark study testing benralizumab for hypereosinophilic syndrome in children, filling a critical gap in treatment options for patients under age 12.
Original Source
Read the full article at Cleveland →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.